Investigation Overview
After the trading for shares of Jiangbo Pharmaceuticals, Inc. (NASDAQ:JGBO) was halted an investigation on behalf of investors of Jiangbo Pharmaceuticals (JGBO) over potential violations of Federal Securities Laws by Jiangbo Pharmaceuticals, Inc. was announced.
The investigation by a law firm focuses on potential securities claims against Jiangbo Pharmaceuticals, Inc resulting from allegations that the company may have issued materially misleading statements and business information to the investing public.
Jiangbo Pharmaceuticals reported substantial increase in its 12months Revenue and Net Income. Jiangbo Pharmaceuticals, Inc. reported an increase from $3.04million to $97.44million within the past four 12months filing periods. It reported an increase in its Net Income over the same time frame from a $5.82million Net Loss to a $29.85million Net Income.
Shares of Jiangbo Pharmaceuticals, Inc. (Public, NASDAQ: JGBO) traded as high as $10.49 in August 2010 and fell to $3.08 per share on May 31, 2011 when the The NASDAQ Stock Market (Nasdaq:NDAQ) announced that trading was halted in Jiangbo Pharmaceuticals, Inc. (Nasdaq:JGBO) for 'additional information requested' from the company.